Neisseria species as pathobionts in bronchiectasis.
Li, L
Mac Aogáin, M
Xu, T
Jaggi, TK
Chan, LLY
Qu, J
Wei, L
Liao, S
Cheng, HS
Keir, HR
Dicker, AJ
Tan, KS
De Yun, W
Koh, MS
Ong, TH
Lim, AYH
Abisheganaden, JA
Low, TB
Hassan, TM
Long, X
Wark, PAB
Oliver, B
Drautz-Moses, DI
Schuster, SC
Tan, NS
Fang, M
Chalmers, JD
Chotirmall, SH
Drautz-Moses, DI
Schuster, SC
Tan, NS
Fang, M
Chalmers, JD
Chotirmall, SH
- Publisher:
- CELL PRESS
- Publication Type:
- Journal Article
- Citation:
- Cell Host Microbe, 2022, 30, (9), pp. 1311-1327.e8
- Issue Date:
- 2022-09-14
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Neisseria species are frequently identified in the bronchiectasis microbiome, but they are regarded as respiratory commensals. Using a combination of human cohorts, next-generation sequencing, systems biology, and animal models, we show that bronchiectasis bacteriomes defined by the presence of Neisseria spp. associate with poor clinical outcomes, including exacerbations. Neisseria subflava cultivated from bronchiectasis patients promotes the loss of epithelial integrity and inflammation in primary epithelial cells. In vivo animal models of Neisseria subflava infection and metabolipidome analysis highlight immunoinflammatory functional gene clusters and provide evidence for pulmonary inflammation. The murine metabolipidomic data were validated with human Neisseria-dominant bronchiectasis samples and compared with disease in which Pseudomonas-, an established bronchiectasis pathogen, is dominant. Metagenomic surveillance of Neisseria across various respiratory disorders reveals broader importance, and the assessment of the home environment in bronchiectasis implies potential environmental sources of exposure. Thus, we identify Neisseria species as pathobionts in bronchiectasis, allowing for improved risk stratification in this high-risk group.
Please use this identifier to cite or link to this item: